Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Uromed

This article was originally published in The Gray Sheet

  • News

Executive Summary

Firm's CaverMap prostate surgical aid, AlloSling tissue graft, and line of brachytherapy introduction insertion needles are exhibited at the recent American Urological Association annual meeting in San Diego. CaverMap, intended to assist in impotence prophylaxis during prostate surgery, assists the location and stimulation of cavernosal nerves. AlloSling, a pre-harvested natural tissue graft material, is used with the Needham, Massachusetts firm's 510(k) cleared Access instruments in female incontinence-correcting sling procdures. The radioactive brachytherapy introduction needles, manufactured by a third party, are intended to pave the way for the third-quarter launch of Uromed's I125 prostate cancer therapy device

Table

View full table

Tags:
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

MT010210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By